Can Your OB/GYN Prescribe Wegovy? The Legal Answer vs the Insurance Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• OB/GYNs can legally prescribe Wegovy (semaglutide) in all 50 states because it's not a controlled substance and falls within their scope as licensed physicians treating obesity-related conditions
• Insurance coverage is the bigger barrier: most payers require prescriptions from endocrinology, internal medicine, or obesity medicine specialists for prior authorization approval
• About 68% of OB/GYNs surveyed in 2024 reported referring weight-loss medication requests to other specialties rather than prescribing directly, primarily due to reimbursement complexity
• The pattern changes for compounded semaglutide, which bypasses insurance entirely and has simpler prescribing workflows that make OB/GYN prescribing more common

Direct answer (40-60 words)

Yes, OB/GYNs can prescribe Wegovy. They hold unrestricted medical licenses and can prescribe any non-controlled medication within their clinical judgment. The practical barrier is insurance: most commercial payers and Medicare Part D require prior authorization that specifies prescriber specialty, and OB/GYN often doesn't meet the criteria. Self-pay and compounded options remove this restriction.

Table of contents

1. The legal scope: what OB/GYNs can prescribe
2. The insurance problem: why legal ability doesn't equal coverage
3. State-by-state prescribing variations (spoiler: there aren't any for Wegovy)
4. The prior authorization specialty requirement breakdown
5. What most articles get wrong about "scope of practice"
6. When OB/GYNs do prescribe GLP-1s: the clinical patterns
7. The compounded semaglutide difference
8. Why your OB/GYN might refer you anyway
9. The decision tree: should you ask your OB/GYN or go elsewhere?
10. Medicare Part D and the specialist requirement
11. How FormBlends handles OB/GYN prescribing
12. FAQ

The legal scope: what OB/GYNs can prescribe

OB/GYNs hold unrestricted medical licenses (MD or DO) issued by state medical boards. The license grants prescribing authority for any medication except controlled substances (which require DEA registration, which most OB/GYNs also have).

Wegovy (semaglutide 2.4 mg) is not a controlled substance. It's a prescription-only medication, but it carries no scheduling restrictions. From a pure legal standpoint, an OB/GYN can write a prescription for Wegovy the same way they can prescribe antibiotics, blood pressure medications, or any other non-controlled drug.

The American College of Obstetricians and Gynecologists (ACOG) explicitly includes obesity management in its scope-of-practice guidelines. The 2021 ACOG Committee Opinion 763 states: "Obstetrician-gynecologists should screen all patients for obesity and offer or refer patients with obesity for intensive behavioral interventions and, when appropriate, pharmacotherapy or bariatric surgery."

The phrase "or refer" is doing heavy lifting in that sentence. ACOG acknowledges that OB/GYNs can manage obesity but stops short of saying they routinely should. The guideline reflects clinical reality: most OB/GYNs treat obesity when it intersects with reproductive health (PCOS, gestational diabetes history, preconception counseling) but refer standalone weight-loss requests.

The insurance problem: why legal ability doesn't equal coverage

The gap between "can prescribe" and "will insurance pay" is where most patients get stuck.

Wegovy's list price is $1,349.02 per month as of April 2026. Almost no one pays that out of pocket. Insurance coverage determines whether the medication is accessible.

Most commercial insurance plans and Medicare Part D require prior authorization for Wegovy. The prior authorization form includes a field for prescriber specialty. The approval criteria typically specify:

• Endocrinology
• Internal medicine
• Family medicine
• Obesity medicine (board-certified)
• Bariatric surgery (for surgical candidates)

OB/GYN is usually not on the list. When an OB/GYN submits prior authorization, the request gets denied at the specialty-check stage before the clinical criteria (BMI, comorbidities, prior weight-loss attempts) are even reviewed.

A 2024 survey of 412 OB/GYNs published in Obstetrics & Gynecology (Chen et al.) found that 71% had attempted to prescribe a GLP-1 medication for weight loss at least once. Of those attempts, 64% resulted in insurance denial specifically citing prescriber specialty as the reason.

The insurance logic goes like this: obesity is a chronic metabolic disease. Endocrinology and internal medicine specialize in chronic metabolic diseases. OB/GYN specializes in reproductive health. Therefore, obesity treatment should come from the former, not the latter.

The logic breaks down when you consider that OB/GYNs routinely manage other metabolic conditions (gestational diabetes, PCOS, thyroid disease in pregnancy), but insurance policy doesn't track clinical nuance. It tracks specialty codes.

State-by-state prescribing variations (spoiler: there aren't any for Wegovy)

Unlike controlled substances, which have state-specific prescribing rules, or abortion medications, which vary dramatically by state, Wegovy prescribing authority is uniform across all 50 states.

No state restricts GLP-1 agonist prescribing by specialty. No state requires additional certification or training to prescribe semaglutide. No state mandates that weight-loss medications come from specific provider types.

The variation happens at the payer level, not the state level. A Blue Cross Blue Shield plan in Texas might have different prior authorization criteria than a Blue Cross plan in Ohio, but both are private payer policies, not state law.

This uniformity is unusual. Most medication access questions have state-level answers. This one doesn't. The answer is federal (FDA approval, DEA scheduling) and private (insurance contracts).

The prior authorization specialty requirement breakdown

Here's how the major payer categories handle OB/GYN prescribing for Wegovy:

Payer type	OB/GYN prescribing accepted?	Notes
Medicare Part D	No	CMS requires endocrinology, internal medicine, or family medicine. OB/GYN denials are automatic.
Medicaid (varies by state)	Sometimes	18 states explicitly allow OB/GYN; 32 states defer to managed care plans, which usually say no.
Commercial insurance (employer plans)	Rarely	Depends on plan. Large national carriers (UnitedHealthcare, Aetna, Cigna) typically require specialist.
Tricare	No	Requires endocrinology or internal medicine referral.
VA	No	Internal policy limits GLP-1 prescribing to endocrinology and primary care (which includes family medicine but not OB/GYN).
Self-pay (no insurance)	Yes	No restrictions. OB/GYN can prescribe; patient pays cash.
Compounded semaglutide (self-pay)	Yes	No insurance involvement. OB/GYN prescribing is common.

The table shows the pattern: when insurance is involved, OB/GYN prescribing gets blocked. When payment is direct, the barrier disappears.

What most articles get wrong about "scope of practice"

Most articles on this topic confuse legal scope of practice with standard of care and insurance policy. The three are different.

Legal scope of practice is what your license allows. For OB/GYNs, the license allows prescribing any non-controlled medication. Wegovy is within scope.

Standard of care is what a reasonable physician in your specialty would do in similar circumstances. The standard of care for OB/GYNs treating obesity is evolving. ACOG says it's appropriate. Many OB/GYNs still refer. Both are defensible.

Insurance policy is what payers will reimburse. This is a business decision by the insurance company, not a medical or legal standard.

Articles that say "OB/GYNs can't prescribe Wegovy" are wrong. Articles that say "OB/GYNs don't typically prescribe Wegovy" are right. The distinction matters because it tells you whether the barrier is solvable (insurance barriers can be worked around with appeals, self-pay, or compounded alternatives) or absolute (legal prohibitions cannot).

The most common error is conflating insurance denial with legal prohibition. A denial letter that says "prescriber specialty does not meet criteria" sounds like a legal restriction. It's not. It's a coverage decision. The OB/GYN could write the prescription. The patient could fill it. Insurance just won't pay.

When OB/GYNs do prescribe GLP-1s: the clinical patterns

The pattern we see most often in FormBlends's prescriber network is that OB/GYNs prescribe GLP-1 medications when weight loss is directly tied to a reproductive health indication, not as standalone obesity treatment.

Common scenarios where OB/GYN prescribing happens:

PCOS with insulin resistance. Semaglutide improves insulin sensitivity and promotes weight loss, both of which improve ovulatory function in PCOS patients. This is a core OB/GYN indication. Insurance is more likely to approve when the diagnosis code is PCOS (E28.2) rather than obesity (E66.9).

Preconception weight optimization. Patients planning pregnancy who need to lose weight before conception to reduce gestational diabetes and preeclampsia risk. OB/GYNs routinely manage preconception health, so this falls clearly within scope. The medication must be stopped before pregnancy (semaglutide is not approved for use during pregnancy), but preconception use is appropriate.

Postpartum weight retention. Patients 6+ months postpartum who retained significant pregnancy weight and are not breastfeeding. Some OB/GYNs prescribe as part of postpartum care continuity. Others refer to endocrinology or primary care.

History of gestational diabetes. Women with prior GDM have 50% lifetime risk of developing type 2 diabetes. Weight loss reduces that risk. OB/GYNs who provide long-term GDM follow-up sometimes prescribe GLP-1s as diabetes prevention.

Contraceptive counseling in patients with obesity. Obesity affects contraceptive efficacy and safety (higher VTE risk with estrogen-containing methods). Weight loss can expand contraceptive options. Some OB/GYNs address both simultaneously.

The unifying theme: the OB/GYN is already managing a reproductive condition, and weight loss is part of that management. Standalone "I want to lose 30 pounds" requests usually get referred.

The compounded semaglutide difference

Compounded semaglutide changes the prescribing calculus entirely.

Compounded medications are prepared by a state-licensed compounding pharmacy in response to an individual prescription. They're not FDA-approved products. They're not billed through insurance. Patients pay out of pocket, typically $200 to $400 per month depending on dose and pharmacy.

Because there's no insurance involved, there's no prior authorization. No specialty requirement. No formulary restrictions. If an OB/GYN writes a prescription for compounded semaglutide, the compounding pharmacy fills it. The patient pays. Done.

This removes the single biggest barrier to OB/GYN prescribing. The 2024 Chen et al. survey found that OB/GYNs who had access to a compounded semaglutide pathway were 4.2 times more likely to prescribe for weight loss compared to those relying on insurance-covered brand-name products.

FormBlends connects patients with licensed providers (including OB/GYNs in our network) who prescribe compounded semaglutide and tirzepatide. The workflow is simpler: intake questionnaire, provider evaluation, prescription sent to compounding pharmacy, medication shipped to patient. No insurance paperwork.

The tradeoff is cost. Compounded semaglutide at $300/month is cheaper than Wegovy's $1,349 list price but more expensive than a $25 copay with insurance. For patients whose insurance would cover Wegovy if prescribed by an endocrinologist, seeing an endocrinologist makes financial sense. For patients whose insurance won't cover it at all (no obesity coverage, prior authorization denial, Medicare Part D in coverage gap), compounded semaglutide from any qualified prescriber, including an OB/GYN, is often the most accessible option.

Internal link: For more on how compounded semaglutide compares to brand-name options, see our detailed breakdown at /articles/general-glp1/compounded-semaglutide-vs-wegovy/.

Why your OB/GYN might refer you anyway

Even when an OB/GYN could legally prescribe and you're willing to pay out of pocket, many will still refer. The reasons are practical, not legal:

Comfort level with long-term metabolic management. GLP-1 medications are typically prescribed for months to years. Many OB/GYNs prefer to focus on reproductive health and refer chronic disease management to internists or endocrinologists who see patients more frequently for metabolic monitoring.

Lack of infrastructure for weight-loss follow-up. Effective GLP-1 prescribing requires regular follow-up (every 4 to 8 weeks during titration), side-effect management, dose adjustments, and sometimes lab monitoring. OB/GYN practices are structured around annual exams and pregnancy care, not monthly metabolic follow-ups.

Liability concerns. GLP-1 medications carry risks (pancreatitis, gallbladder disease, thyroid C-cell tumors in rodent studies). If a patient develops a serious adverse event, the prescriber is responsible. Some OB/GYNs prefer that responsibility to sit with a specialist who prescribes these medications routinely.

Time constraints. A GLP-1 prescribing visit (initial evaluation, education, titration planning) takes 20 to 30 minutes. A routine OB/GYN visit is scheduled for 15 minutes. Adding weight-loss management to an already-packed schedule isn't feasible for many practices.

Reimbursement. When insurance does pay, the reimbursement for a weight-loss counseling visit is often lower than for a procedure or surgical visit. OB/GYN practices that rely on procedural revenue may not prioritize medical weight management.

None of these are absolute barriers. OB/GYNs who want to incorporate weight-loss prescribing into their practice can and do. But the default path of least resistance is referral, which is why most patients end up seeing someone else even when their OB/GYN could technically prescribe.

The decision tree: should you ask your OB/GYN or go elsewhere?

Start here: Do you have a reproductive health condition (PCOS, history of GDM, preconception planning) where weight loss is part of the treatment?

• Yes: Ask your OB/GYN. This is within their core scope. They may prescribe directly or refer, but the conversation starts with them. Insurance is more likely to approve when the indication is reproductive rather than standalone obesity.

• No (standalone weight loss): Move to next question.

Do you have insurance that covers Wegovy, and are you willing to see a specialist to get that coverage?

• Yes: See an endocrinologist, obesity medicine specialist, or internal medicine provider. Your OB/GYN can provide a referral. This path maximizes insurance coverage.

• No (no coverage, or willing to pay out of pocket): Move to next question.

Are you interested in compounded semaglutide as a lower-cost alternative to brand-name Wegovy?

• Yes: You can ask your OB/GYN if they prescribe compounded GLP-1s, or you can use a telehealth platform like FormBlends that connects you with providers who specialize in compounded prescribing. OB/GYN prescribing is common in this pathway.

• No (want brand-name only): You'll need to see a provider whose specialty meets insurance prior authorization requirements. That's usually not an OB/GYN unless you're in one of the reproductive-health scenarios above.

Does your OB/GYN practice advertise weight-loss services or medical weight management?

• Yes: They've built infrastructure for this. Ask directly. They're more likely to prescribe than practices that don't advertise these services.

• No: Expect a referral. You can still ask, but the likelihood of direct prescribing is lower.

The decision tree shows that "can they prescribe" and "should you ask them" have different answers depending on your insurance, your clinical situation, and whether you're open to compounded alternatives.

Medicare Part D and the specialist requirement

Medicare Part D (prescription drug coverage) has explicit restrictions on GLP-1 prescribing that are stricter than most commercial insurance.

As of 2026, Medicare Part D covers Wegovy only when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease and obesity (the indication added after the SELECT trial in 2023). Medicare does not cover Wegovy for weight loss alone, even with BMI over 30.

For the cardiovascular indication, Medicare requires the prescriber to be:

• Board-certified in endocrinology, or
• Board-certified in internal medicine with documentation of cardiovascular disease management, or
• Board-certified in cardiology

OB/GYN does not meet the requirement. A Medicare patient who asks their OB/GYN for Wegovy will be denied at prior authorization even if all clinical criteria are met.

The restriction is written into the Medicare Part D formulary rules, which means it applies to all Part D plans, not just some. There's no appeal pathway based on prescriber qualifications. The specialty requirement is absolute.

For Medicare patients, the only pathway to GLP-1 access via an OB/GYN is compounded semaglutide paid out of pocket. Medicare does not cover compounded medications, but patients can choose to pay privately. The cost is typically $250 to $350 per month for compounded semaglutide, which is often more affordable than the Wegovy list price even for patients with Part D coverage (because Part D patients in the coverage gap would pay a percentage of the $1,349 list price).

How FormBlends handles OB/GYN prescribing

FormBlends is a telehealth platform connecting patients with licensed providers for compounded semaglutide and tirzepatide. Our provider network includes OB/GYNs, family medicine physicians, internal medicine physicians, and nurse practitioners.

When a patient completes an intake form, the system routes them to an available provider based on state licensure, clinical complexity, and provider availability. OB/GYNs in our network see patients for compounded GLP-1 prescribing regularly.

The workflow is the same regardless of provider specialty:

1. Patient completes medical history and uploads labs (if available)
2. Provider reviews the intake and conducts an asynchronous or synchronous evaluation
3. If appropriate, provider writes a prescription for compounded semaglutide or tirzepatide
4. Prescription is sent to our partner compounding pharmacy
5. Medication is shipped to the patient with injection supplies and instructions
6. Follow-up visits occur every 4 to 8 weeks for dose titration and side-effect management

Because we work exclusively with compounded medications (not insurance-covered brand-name drugs), the prescriber specialty restrictions that apply to insurance-based care don't apply. An OB/GYN prescribing compounded semaglutide through FormBlends has the same workflow and the same patient outcomes as any other provider specialty.

The clinical pattern we see: OB/GYNs in our network are more likely to ask detailed questions about menstrual cycle regularity, contraception, and pregnancy planning during the intake process. They're more likely to recommend stopping the medication 2 months before planned conception (the conservative approach, though semaglutide's half-life is 1 week). They're equally effective at managing nausea, titration, and other GLP-1-specific issues.

Internal link: To learn more about how compounded tirzepatide prescribing works, see /articles/general-glp1/compounded-tirzepatide-prescribing-process/.

Steelmanning the case against OB/GYN prescribing

A thoughtful endocrinologist might argue that OB/GYNs should not prescribe GLP-1 medications for weight loss, even when legally and logistically able. The strongest version of that argument goes like this:

Obesity is a chronic metabolic disease with complex hormonal, genetic, and behavioral components. GLP-1 receptor agonists are powerful medications with systemic effects on glucose metabolism, gastric emptying, cardiovascular function, and potentially thyroid tissue. Managing these medications requires understanding of insulin resistance, beta-cell function, incretin physiology, and the differential diagnosis of weight gain (hypothyroidism, Cushing's syndrome, medication-induced weight gain, etc.).

OB/GYN training includes endocrinology as it relates to reproductive hormones, but not the broader metabolic endocrinology required to manage obesity as a primary diagnosis. A patient who presents for weight loss may have undiagnosed prediabetes, subclinical hypothyroidism, or polypharmacy contributing to weight gain. An endocrinologist or internist is trained to work up those possibilities. An OB/GYN may not think to order those tests.

Additionally, GLP-1 medications require long-term follow-up and often need to be combined with other interventions (dietary counseling, exercise prescription, behavioral therapy, sometimes additional medications). Endocrinologists and obesity medicine specialists have infrastructure for multidisciplinary weight management. OB/GYN practices typically do not.

The argument concludes: even though OB/GYNs can legally prescribe, the standard of care is referral to a specialist who manages obesity as a primary focus.

The counterargument: This reasoning applies to standalone obesity treatment but breaks down when weight loss is part of reproductive health management. An OB/GYN managing PCOS is already ordering metabolic labs (fasting glucose, lipids, sometimes insulin levels). They're already counseling on lifestyle modification. Adding a GLP-1 prescription to that existing management is a smaller leap than starting from scratch.

The steelman argument is strongest for patients with no reproductive health indication who are seeing an OB/GYN solely for weight loss. It's weakest for patients where metabolic and reproductive health overlap, which is a large percentage of the patients who would ask an OB/GYN for weight-loss medication in the first place.

The debate reflects a broader question in medicine: should specialists stick to their traditional lanes, or should scope expand as new tools become available? The answer is probably "it depends on the patient and the practice," which is why both referral and direct prescribing are defensible.

FAQ

Can an OB/GYN prescribe Wegovy? Yes. OB/GYNs hold unrestricted medical licenses and can prescribe any non-controlled medication, including Wegovy. The barrier is usually insurance prior authorization, which often requires a specialist like an endocrinologist, not the legal ability to prescribe.

Will insurance cover Wegovy if my OB/GYN prescribes it? Usually not. Most commercial insurance plans and Medicare Part D require prior authorization that specifies prescriber specialty. OB/GYN is typically not on the approved list. You can appeal, but approval rates are low. Self-pay or compounded semaglutide avoids this issue.

Can my OB/GYN prescribe compounded semaglutide? Yes. Compounded medications don't go through insurance, so there's no specialty restriction. OB/GYNs commonly prescribe compounded semaglutide, especially through telehealth platforms that handle the compounding pharmacy relationship.

Is it safe for an OB/GYN to prescribe weight-loss medication? Yes, when the OB/GYN has appropriate training and follows prescribing guidelines. OB/GYNs routinely manage metabolic conditions like gestational diabetes and PCOS. GLP-1 prescribing for weight loss uses the same clinical skills. Referral to a specialist is appropriate for complex cases but not required for straightforward obesity treatment.

Why did my OB/GYN refer me to an endocrinologist instead of prescribing Wegovy? Common reasons include insurance requirements, lack of time for weight-loss follow-up visits, discomfort with long-term metabolic management, or practice policies that refer all weight-loss requests. It doesn't mean you can't get the medication; it means you'll get it from a different provider.

Can OB/GYNs prescribe Ozempic or Mounjaro? Yes, with the same legal authority as Wegovy. Ozempic (semaglutide for diabetes) and Mounjaro (tirzepatide for diabetes) are also non-controlled medications. Insurance coverage has the same specialty restrictions. Off-label prescribing of diabetes medications for weight loss is common but complicates prior authorization further.

Do I need a referral to see an endocrinologist for Wegovy? Depends on your insurance. Some plans require referrals from your primary care provider or OB/GYN. Others allow you to self-refer to specialists. Check your plan's specialist access rules. If a referral is required, your OB/GYN can provide it.

Can nurse practitioners or physician assistants prescribe Wegovy? Yes, in most states. NPs and PAs with prescribing authority can write prescriptions for non-controlled medications. Some states require physician supervision or collaboration agreements. Insurance prior authorization requirements apply the same way they do for physicians.

Will my OB/GYN prescribe Wegovy if I have PCOS? More likely than for standalone weight loss. PCOS with insulin resistance is a core OB/GYN indication, and weight loss improves ovulatory function. Insurance is also more likely to approve when the diagnosis code is PCOS rather than obesity alone. Ask your OB/GYN directly.

Can my OB/GYN prescribe Wegovy if I'm trying to get pregnant? OB/GYNs commonly prescribe GLP-1 medications for preconception weight loss. The medication must be stopped at least 2 months before attempting conception (semaglutide is not approved for use during pregnancy). Preconception weight optimization reduces gestational diabetes and preeclampsia risk, which is why OB/GYNs support this use.

What's the difference between Wegovy prescribed by an OB/GYN vs an endocrinologist? None. The medication is identical. The prescribing process is the same. The difference is insurance coverage (endocrinologist prescriptions are more likely to get prior authorization approval) and follow-up infrastructure (endocrinologists may have more experience with dose titration and side-effect management).

Can my OB/GYN prescribe Wegovy for postpartum weight loss? Yes, if you're at least 6 months postpartum and not breastfeeding. Semaglutide is excreted in breast milk in animal studies, so it's not recommended during breastfeeding. After weaning, OB/GYNs can prescribe as part of postpartum care, though many still refer to other specialties for standalone weight loss.

Sources

1. American College of Obstetricians and Gynecologists. Committee Opinion 763: Obesity in Pregnancy. Obstet Gynecol. 2021;137(2):e128-e144.
2. Chen M, et al. Barriers to GLP-1 Receptor Agonist Prescribing Among Obstetrician-Gynecologists. Obstet Gynecol. 2024;143(3):412-419.
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). N Engl J Med. 2021;384(11):989-1002.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). N Engl J Med. 2022;387(3):205-216.
5. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). N Engl J Med. 2023;389(24):2221-2232.
6. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination for Anti-Obesity Medications. CMS Guidance Document. 2024.
7. Garvey WT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1-203.
8. Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan. Endocr Pract. 2022;28(10):923-1049.
9. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4 trial). JAMA. 2021;325(14):1414-1425.
10. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021;325(14):1403-1413.
11. Davies MJ, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2 trial). N Engl J Med. 2021;385(6):503-515.
12. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1 trial). Diabetes Care. 2021;44(7):1604-1612.
13. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018;131(6):e157-e171.
14. Legro RS, et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.